Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

Francesco Rodeghiero, Roberto Stasi, Terry Gernsheimer et al. · Blood · 2008 · 2.7K citations · Full text

Medicine, Hematology, Immunology +15

Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin

A. R. Ahmed, Zachary Spigelman, Lisa A. Cavacini et al. · New England Journal of Medicine · 2006 · 452 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +8

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab

Roberto Stasi, Nichola Cooper, Giovanni Del Poeta et al. · Blood · 2008 · 406 citations

Life Sciences, Hematology, Immunology +14

Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin

J.A. Stockman · Yearbook of Pediatrics · 2008 · 405 citations

Life Sciences, Immunology, Pharmacotherapy +8